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with non–small cell lung cancer (NSCLC) are predicated
on accurate staging. The presence or absence of mediastinal
lymph node (LN)metastases is a critical component to accu-
rate staging, and therefore a key component of surgicalman-
agement for NSCLC.1 Although the role for mediastinal LN
sampling versus mediastinal LN dissection with regard to
improvement in survival is still controversial, the necessity
for LN assessment for staging purposes is undeniable.1-5
In addition, for early-stage NSCLC, both overall and
disease-free survivals have been associated with the number
of nodes sampled.6 As a result, current guidelines from the
National Comprehensive Cancer Network recommend that
all patients with resectable NSCLC should have an N1 and
N2 node dissection, with at least 3 N2 stations sampled.3
Similar guidelines published by the European Society of
Thoracic Surgeons recommend a complete systematic
nodal dissection.4 Finally, the most recent guidelines from
the American College of Chest Physicians state that there
is sufficient evidence in the literature to support a grade
1B recommendation that intraoperative systematic medias-
tinal LN sampling or dissection be performed.5 Unfortu-
nately, few patients ultimately undergo sufficient LN
dissection, with as many as 40% to 50% of patients having
no mediastinal LNs removed at the time of lung resection.7
Lobectomy by video-assisted thoracoscopic surgery
(VATS) is steadily becoming more commonplace and has
been shown to be associated with equivalent or superior post-
operative outcomes, as well as equivalent oncologic out-
comes.8-10 Lobectomy by VATS with mediastinal LN
dissectionwasfirstdescribed in1995.11Since that time,anum-
ber of studies have been published comparingmediastinal LN
dissection via thoracotomy with VATS.12-18 We review the
technique and efficacy of VATS mediastinal LN dissection.TECHNIQUE
The technique for lymphadenectomy by VATS remains
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tion has been completed. Although visualization can be dif-
ficult, proper use of a 30-degree thoracoscope will facilitate
the dissection. On the right, the dissection is begun at levels
2 and 4 by incising the mediastinal pleura just posterior to
the superior vena cava and then grasping the nodal tissue
with a forceps. The nodal packet is then dissected laterally
from the superior vena cava and trachea, over the ascending
aorta, to the level of the subclavian artery. Judicious use of
electrocautery is necessary to avoid injury to the right vagus
nerve, or more superiorly, the right recurrent laryngeal
nerve. Some surgeons prefer a harmonic scalpel or liberal
use of hemostatic clips to avoid hemorrhage from lymphatic
or bronchial vessels during the dissection. The azygous vein
may be sacrificed if necessary to adequately expose the low-
level 4 nodes.
On the left, with the lung retracted inferiorly, levels 5 and
6 are accessed by incising the pleura overlying the aortic
arch, posterior to the phrenic nerve. The left vagus also
should be identified and preserved. The dissection is then
continued into the aortopulmonary window along the left
main bronchus to remove station 4L. This must be done
carefully to avoid injury to the left recurrent laryngeal
nerve.
Identification of the level 7 LN station begins with re-
tracting the lung medially and dividing the posterior medi-
astinal pleura. On the right, the medial border of the
bronchus intermedius may be followed; on the left, the
mainstem bronchus provides the lateral border. The nodal
packet is dissected free from the underlying posterior peri-
cardium, moving superiorly from the inferior pulmonary
vein until the carina is visualized. Level 8 and 9 LNs are
easily identified and excised when mobilizing the inferior
pulmonary ligament and retracting the lung superiorly.
N1 nodes should be dissected during the course of indi-
vidual hilar bronchovascular dissection. These nodes, levels
10 to 13, should be individually labeled and sent for patho-
logic analysis. In addition, a dialogue between surgeon and
pathologist about the importance of examining LNs within
the lobectomy specimen itself should be made explicit.EFFICACY
Several studies have examined the ability of mediastinal
lymphadenectomy by VATS to effectively dissect and sam-
ple N2 level LNs (Table 1). Kondo and colleagues12 per-
formed the first of these observing 6 patients who first
underwent lobectomy by VATS for a stage I NSCLC of
the right lung with a mediastinal node dissection, followed
by thoracotomy and examination for residual LNs. Anery c September 2012
TABLE 1. Mediastinal lymph node dissection via video-assisted
thoracoscopic surgery versus thoracotomy
No. of lymph nodes removed
Author VATS Thoracotomy
P
value
Kondo and colleagues12 38* —
Sugi and colleagues13 Hilar: 8.2
Mediastinal: 13.0
Hilar: 8.4
Mediastinal: 13.4
.88
Sagawa and colleagues14 39y —
Watanabe and
colleagues15
32.0 29.4 NS
Scott and colleagues16 15 19 .147
Denlinger and
colleagues17
7.1 8.9 .006
No. of lymph node stations sampled
D’Amico and colleagues18 4 4 .06
All values are mean or median as described within each study. VATS, Video-assisted
thoracoscopic surgery;NS, not significant. *There were 1.3 remaining LNs at the time
of subsequent thoracotomy. yThere were 1.2 remaining LNs at the time of subsequent
thoracotomy.
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additional remaining LNs found in only 2 of the 6 patients.
The overall percentage of nodes remaining at the time of
thoracotomy was only 3.4%. A similar study by Sagawa
and colleagues14 examined 29 patients over a 3-year period
who underwent lobectomy by VATS. An average of 40.3
LNs were dissected via VATS on the right side, with only
1.2 remnant nodes. On the left side, an average of 37.1
nodes were resected, again with 1.2 remnant nodes, once
again confirming that near-complete LN dissection was fea-
sible via thoracoscopy.
Sugi and colleagues13 conducted a prospective study in
which 100 patients were randomized to open thoracotomy
or lobectomy by VATS. No differences in tumor character-
istics between the 2 groups were identified. At the conclu-
sion of the study, no difference was noted in the number
of LNs dissected between the open and VATS groups.
A nonrandomized study from 2005 compared the number
of LNs dissected at the time of lobectomy by VATS
(n ¼ 191) with the number of LNs at the time of thoracot-
omy (n ¼ 159) and again found no difference.15 Of note,
a significantly higher percentage of patients in the VATS
group had adenocarcinoma when compared with the thora-
cotomy group.
Three additional studies examining this issue have
been published within the past 2 years.16-18 A secondary
analysis of the American College of Surgeons Oncology
Group Z0030 trial compared patients who underwent
lobectomy by VATS with patients who underwent
thoracotomy.16 A total of 752 of the original participants
of the study were included within the secondary analysis,
of whom 66 underwent thoracoscopic lobectomy and 686
underwent an open procedure. The original trial comparedThe Journal of Thoracic and Capatients who underwent complete mediastinal LN dissec-
tion with those who underwent systematic sampling. Only
those patients undergoing complete dissection were in-
cluded in this secondary analysis. No significant difference
was found in the median number of total LNs retrieved be-
tween the 2 groups. In addition, patients who underwent lo-
bectomy by VATS had fewer chest tubes draining for more
than 7 days (1.5% vs 10.8%, P¼ .029) and a shorter length
of stay (5 vs 7 days, P<.001).
A retrospective review by Denlinger and colleagues17
compared 79 patients who underwent lobectomy by VATS
with 464 patients who underwent open lobectomy for stage
I NSCLC. Their study found a small, although significant,
difference in the number of LNs dissected between each
group (Table 1). Survival between the 2 groups was similar,
although the majority of patients were followed for only 1
year postoperatively. No differencewas noted in the number
of N1 nodes resected. Patients undergoing left-sided resec-
tion had significantly fewer level 7 nodes resected via thor-
acoscopy (0.4 vs 1.0, P< .001), as well as level 5 and 6
nodes (0.5 vs 1.1, P<.04). Most recently, D’Amico and col-
leagues18 examined the National Comprehensive Cancer
Network’s NSCLC Outcomes Database. This study com-
pared the number of nodal stations sampled during thoraco-
scopic lobectomy (n ¼ 199) with the numbered sample
during open lobectomy (n ¼ 189) and found no difference
(4 stations on average in each group).
Perhaps more important than the absolute number of LNs
resected or stations sampled in the determination of effec-
tiveness of lymphadenectomy by VATS, however, is report-
ing of overall and disease-free survival in lobectomy by
VATS series. Suboptimal thoracoscopic LN dissection
might be expected to result in understaging of patients
with NSCLC and be reflected as decreased survival of pa-
tients with early-stage disease. Several large studies have
not shown this to be the case, with both survival and recur-
rence rates being similar in patients treated with VATS or
open lobectomy for stage I disease.9,10CONCLUSIONS
VATS mediastinal LN dissection is equivalent to a com-
parable dissection via a thoracotomy in the hands of an ex-
perienced thoracoscopic surgeon with regard to both
morbidity and oncologic efficacy. We recommend that all
patients undergoing a lobectomy by VATS undergo a com-
plete mediastinal LN evaluation by sampling or complete
dissection at the time of surgical resection.References
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